Chongqing Pharscin Pharmaceutical Co.Ltd(002907) announced on January 16 that the company recently received the drug production license issued by Chongqing food and drug administration, which mainly involves the change of the production site of “orlistat capsule (gyzz: h20103180)”; Meanwhile, the product has been filed and publicized on the official website of the State Food and drug administration.
According to the announcement, the production site of orlistat capsule is changed to: capsule production line of workshop 1, industrial park, Rongchang District, Chongqing; Hard capsule production line of workshop 503, No. 143, Banqiao Road, Changzhou street, Rongchang District, Chongqing. Other contents remain unchanged. Valid until November 9, 2025. The filing date of domestically produced drugs is January 11, 2022.
Data show that orlistat capsule is mainly used for the treatment of obese or overweight patients (body mass index ≥ 24).
Chongqing Pharscin Pharmaceutical Co.Ltd(002907) said that the change of drug production license and the resulting change of drug filing information are conducive to the large-scale production of products and form a large-scale effect. At the same time, it is conducive to the production and supply of the company’s own brand (Quchang) orlistat capsule, so as to better meet the market demand.
